Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: IRELAND

Sector: Diagnostics and Research

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners...
Website: trinitybiotech.com


  • Bad financial results growth rate -3.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-6.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -62.8% (LTM)
  • Share price is 143.6% higher than minimum and 73.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: TRIB
Share price, USD:  (0.0%)0.9147
year average price 0.8685  


year start price 0.7600 2025-02-14

min close price 0.5201 2025-04-08

max close price 1.9100 2025-08-14

current price 0.9147 2026-02-13
Common stocks: 38 327 571

Dividend Yield:  0.0%
EV / Sales: 3.1x
Margin (EBITDA LTM / Revenue): -38.8%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 35
Net Debt ($m): 116
EV (Enterprise Value): 151
EBITDA LTM (млн $): -19
Price to Book: -0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-23globenewswire.com

Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives

2025-12-23globenewswire.com

Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests

2025-08-12globenewswire.com

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

2024-12-18globenewswire.com

Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

2024-11-15seekingalpha.com

Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript

2024-10-08zacks.com

Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial

2024-10-07globenewswire.com

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

2024-09-25zacks.com

Trinity Biotech's Stock Rises After Acquisition of Metabolomics

2024-09-24globenewswire.com

Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

2024-09-18globenewswire.com

Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2025-10-23 2025-12-23 2025-05-15 2024-11-15 2024-10-02 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-09-12 2022-06-30
acceptedDate 2025-10-23 16:32:52 2025-12-23 07:31:14 2025-05-15 16:17:20 2024-12-31 00:00:00 2024-11-15 13:22:01 2024-10-02 11:22:41 2024-02-01 11:37:17 2024-04-30 15:48:25 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2023-05-16 14:54:09 2022-09-12 12:22:17 2022-06-30 2022-05-02 16:13:36 2021-04-30 16:10:25
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 14M 11M 8M 62M 15M 16M 15M 57M 15M 14M 15M 63M 20M 18M 81M 102M
costOfRevenue 8M 7M 6M 40M 10M 10M 10M 37M 10M 9M 9M 53M 17M 12M 55M 53M
grossProfit 6M 4M 2M 21M 5M 6M 5M 19M 4M 5M 6M 22M 2M 7M 33M 49M
grossProfitRatio 0.427 0.395 0.207 0.35 0.362 0.34 0.292 0.362 0.376 0.103 0.353
researchAndDevelopmentExpenses 813 365 646 039 1M 5M 1M 991 000 1M 4M 1M 1M 860 000 4M 1M 984 000 4M 5M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 25M 25M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 7M 5M 29M 7M 6M 7M 31M 8M 8M 9M 29M 6M 7M 25M 25M
otherExpenses 0 0 0 9M 339 000 2M 0 11M 0 0 0 -343 000 -1000 1000 336 000 18M
operatingExpenses 7M 7M 6M 43M 8M 10M 8M 46M 9M 9M 9M 33M 7M 8M 30M 48M
costAndExpenses 15M 14M 12M 83M 18M 20M 18M 84M 19M 18M 19M 82M 24M 20M 77M 102M
interestIncome 995.552 0 1000 0 848 000 0 54 999 1M 389 000 62 000 154 000 303 000 329 000 0 1M 36 000
interestExpense 4M 2M 2M 10M 3M 3M 264 000 10M 2M 4M 3M 25M 2M 18M 7M 7M
depreciationAndAmortization 657 064 665 278 638 476 2M 598 000 153 000 691 000 2M 229 000 484 000 756 000 2M 1M 261 000 3M 3M
ebitda -115 480 -3M -6M -17M -1M -4M -2M -24M -4M -3M -3M -17M -4M 9M 11M 3M
ebitdaratio -0.008 -0.267 -0.772 -0.073 -0.246 -0.162 -0.264 -0.251 -0.213 -0.191 0.465
operatingIncome -536 602 -3M -5M -21M -3M -4M -3M -27M -5M -15M -4M -15M -5M -2M 4M 82 000
operatingIncomeRatio -0.038 -0.277 -0.625 -0.169 -0.256 -0.209 -0.307 -1.069 -0.264 -0.246 -0.11
totalOtherIncomeExpensesNet -5M -3M -4M -10M -2M -3M -180 000 -10M -2M -11M -2M -24M -4M -18M -6M -7M
incomeBeforeTax -5M -6M -9M -31M -5M -7M -3M -37M -6M -19M -6M -44M -9M -20M -2M -7M
incomeBeforeTaxRatio -0.354 -0.524 -1.161 -0.316 -0.435 -0.221 -0.443 -1.339 -0.426 -0.458 -1.088
incomeTaxExpense 72 675 297 704 6004 486 000 -35 000 -131 000 67 000 -59 000 222 000 -267 000 -11 000 -194 000 3000 -30 000 -74 000 -620 000
netIncome -5M -6M -9M -32M -5M -7M -3M -24M -7M -6M -6M -41M -9M -10M 875 000 -6M
netIncomeRatio -0.359 -0.551 -1.162 -0.314 -0.426 -0.226 -0.458 -0.431 -0.425 -0.459 -0.526
eps -0.27 -0.32 -0.48 -1.77 -0.46 -0.71 -0.37 -3.2 -0.88 -0.78 -0.17 -6 -0.23 -0.395 0.21 -1.54
epsdiluted -0.27 -0.32 -0.48 -0.46 -0.71 -0.37 -0.88 -0.78 -0.17 -0.23 -0.395
weightedAverageShsOut 19M 19M 18M 18M 10M 9M 9M 8M 8M 8M 38M 7M 38M 25M 4M 4M
weightedAverageShsOutDil 19M 19M 18M 18M 10M 9M 9M 8M 8M 8M 38M 8M 38M 25M 5M 4M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-04-30 2023-05-16 2022-05-02 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -10M -9M -24M -6M -7M
ebit -19M -26M -19M 8M 118 000
nonOperatingIncomeExcludingInterest -2M -1M 4M -3M -18M
netIncomeFromContinuingOperations -31M -37M -44M -2M -6M
netIncomeFromDiscontinuedOperations -573 000 13M 3M 3M -375 000
otherAdjustmentsToNetIncome 0 0 0 -3M 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -32M -24M -41M 875 000 -6M
epsDiluted -1.77 -3.2 -5.2 0.16 -1.54

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-12 2022-06-30 2021-12-31 2020-12-31
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2025-10-23 2025-12-23 2025-05-15 2024-11-15 2024-10-02 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-09-12 2022-06-30
acceptedDate 2025-10-23 16:32:52 2025-12-23 07:31:14 2025-05-15 16:17:20 2024-12-31 00:00:00 2024-11-15 13:22:01 2024-10-02 11:22:41 2024-02-01 11:37:17 2024-04-30 15:48:25 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2023-05-16 14:54:09 2022-09-12 12:22:17 2022-06-30 2022-05-02 16:13:36 2021-04-30 16:10:25
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 1M 2M 4M 5M 0 5M 6M 4M -13M -13M -14M 7M 0 10M 26M 27M
shortTermInvestments 0 0 0 0 0 0 0 0 19M 27M 17M 0 0 0 0 0
cashAndShortTermInvestments 1M 2M 4M 5M 3M 5M 6M 4M 6M 14M 4M 7M 7M 10M 26M 27M
netReceivables 15M 11M 11M 15M 21M 18M 18M 13M 17M 16M 15M 16M 19M 18M 16M 25M
inventory 19M 20M 20M 19M 22M 23M 23M 20M 21M 23M 22M 23M 24M 29M 29M 30M
otherCurrentAssets 0 0 0 0 0 0 299 000 0 2M 2M 18M 1000 0 0 0 0
totalCurrentAssets 36M 33M 36M 41M 46M 46M 46M 39M 44M 53M 58M 47M 50M 57M 73M 83M
propertyPlantEquipmentNet 4M 4M 4M 5M 4M 4M 3M 2M 2M 2M 5M 6M 6M 6M 6M 9M
goodwill 0 0 0 14M 0 0 0 0 0 0 0 13M 0 0 13M 13M
intangibleAssets 58M 56M 54M 38M 0 42M 39M 16M 16M 16M 0 23M 0 0 23M 21M
goodwillAndIntangibleAssets 58M 56M 54M 51M 47M 42M 39M 16M 16M 16M 21M 35M 37M 39M 36M 34M
longTermInvestments 3M 3M 3M 2M 0 193 000 232 000 214 000 196 000 214 000 2M 212 000 0 0 151 000 441 000
taxAssets 4M 4M 4M 4M 694 000 2M 2M 2M 2M 1M 4M 4M 5M 5M 4M 4M
otherNonCurrentAssets 28 000 28 000 27 999 194 000 233 000 79 000 79 000 43 000 98 000 108 000 272 000 55 000 302 000 347 000 56 000 64 000
totalNonCurrentAssets 68M 67M 64M 62M 51M 48M 44M 20M 20M 19M 33M 45M 48M 50M 46M 47M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 104M 100M 100M 103M 97M 94M 90M 59M 64M 72M 91M 92M 98M 107M 119M 130M
accountPayables 30M 26M 25M 7M 25M 23M 21M 4M 11M 13M 13M 6M 14M 12M 7M 7M
shortTermDebt 2M 3M 2M 210 000 2M 2M 2M 210 000 2M 2M 2M 210 000 210 000 2M 83M 3M
taxPayables 0 0 0 1M 333 000 283 000 337 000 279 000 252 000 287 000 33 000 28 000 21 000 21 000 420 000 842 000
deferredRevenue 0 0 0 197 000 0 283 001 337 000 50 000 0 0 83 000 114 000 0 0 141 000 4M
otherCurrentLiabilities 2M 3M 3M 3M 50 000 -516 002 50 000 160 000 302 000 337 000 1M 153 000 71 000 50 000 249 000 760 000
totalCurrentLiabilities 34M 32M 30M 32M 28M 26M 23M 15M 13M 15M 16M 17M 15M 14M 100M 27M
longTermDebt 115M 110M 106M 88M 91M 91M 73M 55M 65M 65M 75M 58M 58M 57M 0 83M
deferredRevenueNonCurrent 0 0 0 0 0 0 10M 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 5M 5M 5M 5M 2M 4M 3M 2M 2M 2M 5M 5M 5M 5M 5M 5M
otherNonCurrentLiabilities 5M 3M 3M 4M 2M 3M 3M 526 000 1M 2M 2M 2M 62M 15M 0 1M
totalNonCurrentLiabilities 124M 118M 113M 106M 96M 98M 90M 68M 68M 69M 82M 77M 77M 77M 19M 106M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 11M 10M 13M 12M 12M 10M 13M 13M 13M 14M 14M 0 2M 16M 19M
totalLiabilities 158M 149M 143M 138M 124M 124M 113M 83M 81M 83M 98M 94M 91M 91M 119M 133M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 39 999 4M 4M 4M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 1M 1M
retainedEarnings -99M -94M -88M -79M -62M -58M -51M -49M -42M -36M -31M -27M -18M -9M 13M 11M
accumulatedOtherComprehensiveIncomeLoss 5M 906 000 946 000 -5M -6M 1M 927 999 1M -6M -6M -6M -6M -6M -5M -5M -5M
othertotalStockholdersEquity 39M 39M 39M 39M 25M 25M 28M 28M 28M 28M 28M
totalStockholdersEquity -55M -50M -44M -35M -26M -29M -23M -24M -17M -11M -7M -2M 7M 16M -319 000 -2M
totalEquity -55M -50M -44M -35M -26M -29M -23M -24M -17M -11M -7M -2M 7M 16M -319 000 -2M
totalLiabilitiesAndStockholdersEquity 104M 100M 100M 97M 94M 90M 64M 72M 91M 98M 107M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 104M 100M 100M 103M 97M 94M 90M 59M 64M 72M 91M 92M 98M 107M 119M 130M
totalInvestments 3M 3M 3M 2M 0 193 000 232 000 214 000 19M 28M 2M 212 000 0 0 151 000 441 000
totalDebt 117M 113M 108M 101M 94M 93M 86M 67M 67M 67M 77M 72M 58M 59M 99M 104M
netDebt 116M 111M 104M 96M 94M 88M 80M 64M 80M 81M 91M 52M 58M 49M 73M 77M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-04-30 2023-05-16 2022-05-02 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 13M 11M 13M 14M 21M
otherReceivables 1M 2M 3M 2M 3M
prepaids 2M 2M 2M 2M 1M
totalPayables 13M 5M 7M 7M 8M
otherPayables 6M 1M 396 000 451 000 842 000
accruedExpenses 14M 8M 9M 8M 9M
capitalLeaseObligationsCurrent 2M 2M 2M 2M 2M
capitalLeaseObligationsNonCurrent 10M 11M 12M 14M 17M
treasuryStock -25M -25M -25M -25M -25M
additionalPaidInCapital 63M 47M 46M 16M 16M
otherTotalStockholdersEquity 7M 0 7M 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2025-10-23 2025-12-23 2025-05-15 2024-11-15 2024-10-02 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-09-12 2022-06-30
acceptedDate 2025-10-23 16:32:52 2025-12-23 07:31:14 2025-05-15 16:17:20 2024-12-31 00:00:00 2024-11-15 13:22:01 2024-10-02 11:22:41 2024-02-01 11:37:17 2024-04-30 15:48:25 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2023-05-16 14:54:09 2022-09-12 12:22:17 2022-06-30 2022-05-02 16:13:36 2021-04-30 16:10:25
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -5M -6M -9M -32M -5M -7M -3M -24M -7M -6M -6M -41M -9M -22M 875 000 -6M
depreciationAndAmortization 657 064 665 278 638 476 2M 598 000 153 000 691 000 2M 229 000 484 000 602 000 2M 744 000 261 000 3M 3M
deferredIncomeTax 0 0 0 486 000 -35 000 -131 000 67 000 -59 000 222 000 -267 000 -11 000 -192 000 3000 -29 000 -167 000 -182 000
stockBasedCompensation 0 0 0 1M 250 000 114 000 812 000 2M 738 000 975 000 1M 2M 119 000 122 000 1M 792 000
changeInWorkingCapital 550 290 1M 3M 6M -2M 2M -2M -3M -2M -1M -1M -2M 153 000 -2M -172 000 4M
accountsReceivables 0 0 0 -2M 0 0 0 1M 0 0 0 -966 000 0 0 6M -2M
inventory 0 0 0 -2M 0 0 0 -971 000 0 0 0 -877 000 0 0 -4M -3M
accountsPayables 0 0 0 8M 0 0 0 -3M 0 0 0 181 000 0 0 -8M 5M
otherWorkingCapital 550 290 1M 3M 0 -2M 2M -2M -478 000 -2M 0 0 0 0 0 6M 5M
otherNonCashItems 4M 3M 2M 18M 2M 4M 1M 11M 3M 2M 3M 38M 9M 25M 9M 22M
netCashProvidedByOperatingActivities -71 447 -2M -3M -4M -4M -1M -5M -12M -5M -4M -3M -921 000 676 000 956 000 13M 24M
investmentsInPropertyPlantAndEquipment -1M -2M -2M -405 000 -110 000 -72 000 -1M -803 000 -620 000 -564 000 -629 000 -6M -1M 383 000 -9M -10M
acquisitionsNet 0 0 0 -13M -403 000 0 -12M 28M -266 000 28M 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 -700 000 0 0 -700 000 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 -3M -3M -14M -758 000 0 0 0 -1M
netCashUsedForInvestingActivites -1M -2M -2M -3M -3M -14M -886 000 28M -1M -1M -1M
debtRepayment 2M 2M 4M -678 000 6M -22M -571 000 -11M -599 000 -684 000 -36M
commonStockIssued -2132 2970 548 409 7M 269 999 -269 999 0 0 0 0 25M
commonStockRepurchased 0 0 0 0 0 -269 999 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -797 327 -804 693 -736 550 -2M -1 -270 000 -2M -3M 2M -2M 11M
netCashUsedProvidedByFinancingActivities 1M 1M 4M 4M 6M 21M -2M -13M 2M -2M 484 000
effectOfForexChangesOnCash -8469 54 590 29 844 -175 000 5000 -108 000 21 000 -44 000 14 000 85 000 14 000 -112 000 -179 000 -153 000 55 000 86 000
netChangeInCash -205 000 -3M -1M 1M -2M -459 000 2M -3M -8M 10M -2M -19M -3M 441 000 -1M 11M
cashAtEndOfPeriod 1M 2M 4M 5M 3M 5M 6M 4M 6M 14M 4M 7M 7M 10M 26M 27M
cashAtBeginningOfPeriod 2M 4M 5M 4M 5M 6M 4M 7M 14M 4M 7M 26M 10M 10M 27M 16M
operatingCashFlow -71 447 -2M -3M -4M -4M -3M -5M -12M -5M -4M -3M -921 000 676 000 956 000 13M 24M
capitalExpenditure -5662 -37 700 -56 037 -10M -3M -3M -1M -803 000 -620 000 -564 000 -629 000 -6M -1M -1M -9M -10M
freeCashFlow -77 110 -2M -3M -14M -6M -4M -6M -12M -5M -5M -3M -7M -648 000 -77 000 5M 14M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-04-30 2023-05-16 2022-05-02 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -10M -2M 0 0 0
netCashProvidedByInvestingActivities -23M 25M -6M -9M -10M
netDebtIssuance 28M -7M -27M -3M -3M
longTermNetDebtIssuance 28M -7M 60M -1M -3M
shortTermNetDebtIssuance 0 0 -87M -2M 0
netStockIssuance 7M 0 25M 0 0
netCommonStockIssuance 7M 0 25M 0 0
commonStockIssuance 7M 0 25M 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -6M -9M -11M -3M 524 000
netCashProvidedByFinancingActivities 29M -16M -12M -6M -3M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2024 q3
2024-11-15 ET (fiscal 2024 q3)
2024 q2
2024-08-16 ET (fiscal 2024 q2)
2024 q1
2024-05-23 ET (fiscal 2024 q1)
2023 q4
2024-01-31 ET (fiscal 2023 q3)
2023 q3
2023-10-03 ET (fiscal 2023 q2)
2023 q2
2023-07-06 ET (fiscal 2023 q1)
2022 q4
2023-03-23 ET (fiscal 2022 q4)
2022 q3
2022-12-15 ET (fiscal 2022 q3)
2022 q2
2022-06-30 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 08:55 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 07:40 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 07:40 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 07:31 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 07:31 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-23 07:31 ET
Trinity Biotech plc reported for 2025 q3
SEC form 6
2025-12-18 18:34 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-12-18 18:34 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-11-21 10:02 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-11-21 10:02 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-11-18 11:30 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-11-18 11:30 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-10-23 20:32 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-10-23 20:32 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-10-23 20:32 ET
Trinity Biotech plc published news for 2025 q3
SEC form 6
2025-09-30 20:00 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-08 10:03 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-08 10:03 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-08 10:03 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-08 10:03 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-08 10:03 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-02 18:17 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-09-02 18:17 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-20 18:18 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-20 18:18 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-15 14:24 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-15 14:24 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-12 20:33 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-12 20:33 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-12 20:33 ET
Trinity Biotech plc reported for 2025 q2
SEC form 6
2025-08-12 20:33 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-08 10:00 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-08-08 10:00 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-07-24 18:38 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-07-24 18:38 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-07-01 14:27 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-07-01 14:27 ET
Trinity Biotech plc published news for 2025 q2
SEC form 6
2025-06-24 19:03 ET
Trinity Biotech plc published news for 2025 q1
SEC form 6
2025-06-24 19:03 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 20
2025-05-15 21:41 ET
Trinity Biotech plc published news for 2025 q1
SEC form 6
2025-05-15 20:17 ET
Trinity Biotech plc published news for 2025 q1
SEC form 6
2025-05-15 20:17 ET
Trinity Biotech plc reported for 2025 q1
SEC form 6
2025-05-15 20:17 ET
Trinity Biotech plc published news for 2025 q1
SEC form 6
2025-04-04 12:39 ET
Trinity Biotech plc published news for 2025 q1
SEC form 6
2025-03-14 20:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-03-14 20:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-03-13 11:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-03-13 11:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-02-28 08:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-02-28 08:30 ET
Trinity Biotech plc reported for 2024 q4
SEC form 6
2025-02-28 08:30 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-02-06 14:00 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-02-06 14:00 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-02-04 13:36 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-01-29 22:15 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-01-28 16:33 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2025-01-28 16:33 ET
Trinity Biotech plc published news for 2024 q4
SEC form 6
2024-11-15 13:22 ET
Trinity Biotech plc published news for 2024 q3
SEC form 6
2024-11-15 13:22 ET
Trinity Biotech plc reported for 2024 q3
SEC form 6
2024-11-07 12:33 ET
Trinity Biotech plc published news for 2024 q3
SEC form 6
2024-11-07 12:33 ET
Trinity Biotech plc published news for 2024 q3
SEC form 6
2024-10-02 00:00 ET
Trinity Biotech plc published news for 2024 q3
SEC form 6
2024-10-02 00:00 ET
Trinity Biotech plc published news for 2024 q3
SEC form 6
2024-10-02 00:00 ET
Trinity Biotech plc reported for 2024 q3
SEC form 6
2024-07-12 17:03 ET
Trinity Biotech plc published news for 2024 q2
SEC form 6
2024-07-12 17:03 ET
Trinity Biotech plc published news for 2024 q2
SEC form 6
2024-07-12 17:03 ET
Trinity Biotech plc published news for 2024 q2
SEC form 6
2024-07-11 06:55 ET
Trinity Biotech plc published news for 2024 q2
SEC form 6
2024-07-11 06:55 ET
Trinity Biotech plc published news for 2024 q2
SEC form 6
2024-04-30 12:28 ET
Trinity Biotech plc published news for 2024 q1
SEC form 6
2024-04-30 12:28 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 20
2024-04-30 00:00 ET
Trinity Biotech plc published news for 2024 q1
SEC form 6
2024-04-05 13:05 ET
Trinity Biotech plc published news for 2024 q1
SEC form 6
2024-04-05 13:05 ET
Trinity Biotech plc published news for 2024 q1
SEC form 6
2024-02-16 18:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:00 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:00 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:37 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:37 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-01-02 14:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-01-02 14:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2023-11-29 09:00 ET
Trinity Biotech plc published news for 2023 q3
SEC form 6
2023-11-29 09:00 ET
Trinity Biotech plc published news for 2023 q3
SEC form 6
2023-09-12 16:04 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-09-06 16:04 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-09-05 15:38 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-07-10 06:02 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-05-16 14:54 ET
Trinity Biotech plc published news for 2023 q1
SEC form 20
2023-05-16 00:00 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-08 09:04 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-01 16:15 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-01 13:43 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-04-25 16:40 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-04-24 07:26 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-03-27 11:38 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2023-03-27 06:01 ET
Trinity Biotech plc reported for 2022 q4
SEC form 6
2023-02-22 12:11 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2023-01-10 16:05 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2022-12-16 10:59 ET
Trinity Biotech plc reported for 2022 q3
SEC form 6
2022-12-09 10:52 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-15 00:00 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-04 11:08 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-04 06:50 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-02 12:56 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-10-27 08:56 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-10-04 06:12 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-09-30 10:55 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-16 11:25 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-12 12:31 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-12 12:22 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-07-01 10:21 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-05-25 15:24 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-23 12:06 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-09 09:12 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-02 16:13 ET
Trinity Biotech plc published news for 2022 q1
SEC form 20
2022-05-02 00:00 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-04-11 12:22 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-04-11 08:15 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-02-11 06:18 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-28 07:12 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-25 12:12 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-06 16:01 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2021-12-23 17:00 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-12-23 09:33 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-12-16 07:25 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-09-30 09:38 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:36 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:35 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:33 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-09 15:31 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-07-19 16:23 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-05-27 06:01 ET
Trinity Biotech plc published news for 2021 q1
SEC form 6
2021-04-30 16:10 ET
Trinity Biotech plc published news for 2021 q1
SEC form 20
2021-04-30 00:00 ET
Trinity Biotech plc published news for 2021 q1
SEC form 6
2021-03-30 10:30 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2021-03-26 12:30 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2021-01-05 12:05 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2020-12-08 09:50 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-11-24 08:57 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-11-17 12:19 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-10-28 11:23 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-10-28 11:21 ET
Trinity Biotech plc published news for 2020 q3